Skip to main content
SpringerLink
Log in

Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Direct oral anticoagulants (DOACs) have become an attractive option for the treatment of venous thromboembolism (VTE) in cancer patients. However, their use is currently not recommended as first-line treatment by national guidelines due to limited data in this patient population. The objective of this study was to evaluate the practice and safety patterns of DOACs when used for VTE treatment in the oncology population. This study was a retrospective chart review of adult cancer patients treated at Hackensack University Medical Center from January 2013 to October 2015 who received dabigatran, rivaroxaban, or apixaban for VTE treatment. Of 126 patients screened, 39 patients were included. Thirty-five patients received rivaroxaban and four patients received apixaban. Ten of 39 patients (26%) were not receiving a DOAC dosage consistent with the package insert. No patients experienced clinically significant bleeding, while four patients experienced a minor bleed. Four of 14 thrombocytopenic patients (29%) did not have their DOAC dose held for thrombocytopenia. All patients had their DOACs appropriately held for procedures. Increased education on dosing DOACs according to the package insert is warranted for oncology prescribers. Despite the increased risk for bleeding in cancer patients, no clinically significant bleeding events were identified in our patient cohort. This data suggests that the use of DOACs may be safe to use for VTE treatment in cancer patients and may provide foundation for larger, randomized controlled trials to determine whether DOACs should be used for VTE treatment in cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Noble S, Pasi J (2010) Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer 102:S2–S9

    Article  PubMed  PubMed Central  Google Scholar 

  2. National Comprehensive Cancer Network (NCCN) (2018) NCCN Clinical Practice Guidelines in Oncology. Cancer-associated venous thromboembolic disease version 2.2018

  3. Gómez-Outes A, Suárez-Gea ML, Lecumberri R, Terleira-Fernández AI, Vargas-Castrillón E, Rocha E (2013) Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag 9:207–228

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Lee AYY, Peterson EA (2013) Treatment of cancer-associated thrombosis. Blood 122:2310–2317

    Article  CAS  PubMed  Google Scholar 

  5. Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falang A (2015) Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology practice guideline update 2014. J Clin Oncol 33:654–656

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Pradaxa [package insert] (2015) Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield

  7. Xarelto [package insert] (2015) Janssen Pharmaceuticals, Inc, Titusville

  8. Eliquis [package insert] (2015) Bristol-Myers Squibb Company, Princeton

  9. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, RE-COVER Study Group (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361:2342–2352

    Article  CAS  PubMed  Google Scholar 

  10. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S, EINSTEIN Investigators (2010) Oral rivaroxaban for the treatment of symptomatic venous thromboembolism. N Engl J Med 363:2499–2510

    Article  CAS  PubMed  Google Scholar 

  11. Büller HR, Prins MH, Lensing AW, Decousus H, Minar E, Chulmsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowirz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A, EINSTEIN-PE Investigators (2010) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297

    Google Scholar 

  12. Agnelli G, Büller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, AMPLIFY Investigators (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808

    Article  CAS  PubMed  Google Scholar 

  13. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vitch JRE, Wells P, Woller SC, Moores L (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149:315–352

    Article  PubMed  Google Scholar 

  14. Gon Y, Sakaguchi M, Takasugi J, Mochizuki H (2017) Ischemic stroke in cancer patients treated with direct oral anticoagulants for venous thromboembolism. Thromb Res 154:16–18

    Article  CAS  PubMed  Google Scholar 

  15. Steinberg BA, Piccini JP (2014) Anticoagulation in atrial fibrillation. BMJ 348:g2116

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, NewYork-Presbyterian Hospital, Columbia University Irving Medical Center, New York, NY, USA

    Jessica Hedvat

  2. Department of Pharmacy, Hackensack University Medical Center, Hackensack, NJ, USA

    Christina Howlett & Ruchi Patel

  3. Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ, USA

    Christina Howlett

  4. John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

    James McCloskey

Authors
  1. Jessica Hedvat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christina Howlett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James McCloskey
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ruchi Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jessica Hedvat.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hedvat, J., Howlett, C., McCloskey, J. et al. Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population. J Thromb Thrombolysis 46, 483–487 (2018). https://doi.org/10.1007/s11239-018-1731-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-018-1731-1

Keywords

Search

Navigation